Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.37 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19631090 | 1.00 | NAAA (0.41) | NAAAEPHX1CA2FAAHTSHR | |
| SCHEMBL18202108 | 1.00 | NAAA (0.41) | NAAAEPHX1CA2FAAHTSHR | |
| SCHEMBL21509280 | 1.00 | NAAA (0.41) | NAAAEPHX1CA2FAAHTSHR | |
| SCHEMBL22642575 | 1.00 | NAAA (0.41) | NAAAEPHX1CA2FAAHTSHR | |
| SCHEMBL25409594 | 1.00 | NAAA (0.41) | NAAAEPHX1CA2FAAHTSHR | |
| SCHEMBL24240570 | 1.00 | NAAA (0.41) | NAAAEPHX1CA2FAAHTSHR | |
| SCHEMBL24858970 | 1.00 | NAAA (0.41) | NAAAEPHX1CA2FAAHTSHR | |
| SCHEMBL24164048 | 1.00 | NAAA (0.41) | NAAAEPHX1CA2FAAHTSHR | |
| SCHEMBL22920361 | 1.00 | NAAA (0.41) | NAAAEPHX1CA2FAAHTSHR | |
| SCHEMBL31283892 | 1.00 | NAAA (0.41) | NAAAEPHX1CA2FAAHTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230044692-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | MODERNATX, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20190275170-A1 | POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME | MODERNATX, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10238731-B2 | Chikagunya virus RNA vaccines | MODERNATX, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180008694-A1 | CHIKAGUNYA VIRUS RNA VACCINES | MODERNATX, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| US-20170340725-A1 | COMBINATION PIV3/HMPV RNA VACCINES | MODERNATX, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340725-A1 | COMBINATION PIV3/HMPV RNA VACCINES | MODERNATX, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340725-A1 | COMBINATION PIV3/HMPV RNA VACCINES | RBM3, NSUN3, ELAVL3 | NAAA 2007/4885EPHX1 4192/4885CA2 2494/4885 |
| US-20180008694-A1 | CHIKAGUNYA VIRUS RNA VACCINES | CHIA, EIF2AK2, CHI3L1 | NAAA 1371/4885EPHX1 3239/4885CA2 3358/4885 |
| US-20230044692-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | NSUN2, NSUN3, RNMT | NAAA 3266/4885EPHX1 3542/4885CA2 4206/4885 |
| US-10238731-B2 | Chikagunya virus RNA vaccines | CHIA, EIF2AK2, CHI3L1 | NAAA 1371/4885EPHX1 3239/4885CA2 3358/4885 |
| US-20190275170-A1 | POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME | AARS1, IARS1, NOTCH1 | NAAA 1119/4885EPHX1 2183/4885CA2 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.